ir.citiuspharma.comCitius Pharmaceuticals Issues Shareholder Letter with
ir.citiuspharma.com Profile
Ir.citiuspharma.com is a subdomain of citiuspharma.com, which was created on 2007-01-26,making it 17 years ago.
Description：Feb 16 2021 · To read the Shareholder Letter in its entirety please visit the Companys Investor Info website at ircitiuspharmacom About Citius Pharmaceuticals Inc Citius is a specialty...
Discover ir.citiuspharma.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.citiuspharma.com Information
| HomePage size: 62.85 KB |
| Page Load Time: 0.125405 Seconds |
| Website IP Address: 54.225.186.162 |
ir.citiuspharma.com Similar Website
| Visa Sponsor Letter Template: Creating an Effective Document for Sponsorship - LoginTekno |
| Letter from Hardscrabble Creek – A Pagan Studies Blog by Chas S. Clifton |
| Four Corners Property Trust, Inc. - Shareholder focused, value driven |
| The Most Accurate Line Of Channel Letter Bending Machines |
| Resume/CV + Cover Letter = Headache ? | |
| Shareholder Education | Broadridge |
| Professional Resume, Cover Letter and LinkedIn Writing Services - Resume Services | TopResume |
| Spartan Life Welcome Letter | Office of Spartan Experiences | Michigan State University |
| Word words-that-start-with-the-letter-y meaning. Word words-that-start-with-the-letter-y definition. |
| Primerica Shareholder Services |
| Shareholder Portal |
| Elder Law Issues - Fleming & Curti, PLC - Fleming & Curti News and ArticlesElder Law Issues — Flemin |
| Lifeline Pharmaceuticals, LLC’s Login Page | Lifeline Pharmaceuticals, LLC |
| Aethlon Medical Releases Shareholder Update Aethlon |
| United States Lime & Minerals – Shareholder |
ir.citiuspharma.com PopUrls
| First Amendment, dated October 15, 2015 ... https://ir.citiuspharma.com/quarterly-reports/content/0001213900-19-002563/f10q1218ex10-2_citius.htm |
| Form of Securities Purchase Agreement, dated May ... https://ir.citiuspharma.com/all-sec-filings/content/0001213900-20-012809/ea0121848ex10-1_citiuspharma.htm |
ir.citiuspharma.com Httpheader
| Date: Sat, 08 May 2021 12:59:18 GMT |
| Server: Apache |
| Expires: Thu, 19 Nov 1981 08:52:00 GMT |
| Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0 |
| Pragma: no-cache |
| Vary: Accept-Encoding |
| Content-Encoding: gzip |
| Content-Length: 11700 |
| Keep-Alive: timeout=5, max=100 |
| Connection: Keep-Alive |
| Content-Type: text/html; charset=UTF-8 |
ir.citiuspharma.com Meta Info
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
| charset="utf-8"/ |
| content="Citius Pharmaceuticals, Inc." property="og:site_name"/ |
| content="Investor Relations" property="og:title"/ |
| content="website" property="og:type"/ |
| content="https://d1io3yog0oux5.cloudfront.net/_0d5e6fc1ec98ebff1fa1d29ba6bc297f/citiuspharma/db/269/770/social_image_resized.jpg" property="og:image"/ |
| content="summary_large_image" name="twitter:card"/ |
| content="https://ir.citiuspharma.com" property="og:url"/ |
| content="noindex,follow" name="robots" |
| content="en_US" property="og:locale" |
| content="Citius seeks to leverage the FDA’s 505(b)(2) pathway for new drug approvals and bring products to market faster and with less cost as compared to other FDA new drug approval pathways." name="twitter:description" |
| content="Development and Commercialization Strategy – Citius Pharmaceuticals" name="twitter:title" |
| content="https://d1io3yog0oux5.cloudfront.net/_0d5e6fc1ec98ebff1fa1d29ba6bc297f/citiuspharma/files/theme/site-files/20181213/wp-content/uploads/2018/09/microscope1.jpg" name="twitter:image" |
| content="WordPress 4.9.9" name="generator" |
| content="https://d1io3yog0oux5.cloudfront.net/_0d5e6fc1ec98ebff1fa1d29ba6bc297f/citiuspharma/files/theme/site-files/20181213/2018CP/wp-content/uploads/2018/09/CitiusFavicon2.png" name="msapplication-TileImage" |
ir.citiuspharma.com Ip Information
| Ip Country: United States |
| City Name: Ashburn |
| Latitude: 39.0469 |
| Longitude: -77.4903 |
ir.citiuspharma.com Html To Plain Text
Home Overview Company Overview Development Strategy News & Media Leadership Board of Directors Scientific Advisory Board Careers Mino-Lok Overview Mino-Lok Medical Need Mino-Lok About CRBSIs Clinical Data Mino-Lok QIDP/Fast Track Mino-Lok Phase 3 Mino-Lok Halo-Lido About Halo-Lido Medical Need Halo-Lido Hemorrhoids Clinical Data Mino-Wrap About Mino-Wrap Medical Need Mino-Wrap Opportunity Partnering Opportunities Investor Info Investor Overview News / Events Press Releases In the News IR Calendar Email Alerts Company Info Profile Presentations Management Team Contacts FAQ Financial Info Balance Sheet Income Statement Cash Flow Financial Results Stock Data Quote Charts Historical Data SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Governance Documents Board of Directors Investor Tools Email Alerts Fact Sheet Contacts RSS News Feed Contact HomeInvestor Relations Investor Relations February 2021 Shareholder Letter Latest News Citius Pharmaceuticals to Present Mino-Lok® and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13 May 4, 2021 View All News Upcoming Events Benzinga Global Small Cap Conference May 13, 2021 • 1:50pm EDT View All Events Latest Financial Results Q1 2021 Quarter Ended Dec 31, 2020 10-Q Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing Fiscal Year Ended Sep 30, 2020 View Filing Email Alerts Stay informed and receive company updates straight to your inbox Sign up today Stock Information Company Overview February 2021 Shareholder Letter CTXR Presentation - Spring 2021 Download CTXR Presentation - Spring 2021 Leadership Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success. View Management Team View Board of Directors Investor Contact Information Company Citius Pharmaceuticals, Inc. 11 Commerce Drive First Floor Cranford, NJ 07016 T: 908-967-6677 info@citiuspharma.com Investor Relations Andrew Scott VP of Investor Relations T: 908-967-6677 ext. 105 Transfer Agent VStock Transfer LLC 18 Lafayette Place Woodmere, NY 11598 T: 212-828-8436 www.vstocktransfer.com Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor | Cranford, NJ 07016 908.967.6677 | info@citiuspharma.com © 2021 Citius Pharmaceuticals | Disclaimer & Terms of Use ...
ir.citiuspharma.com Whois
Domain Name: CITIUSPHARMA.COM Registry Domain ID: 777728357_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.tucows.com Registrar URL: http://www.tucows.com Updated Date: 2024-05-14T15:17:37Z Creation Date: 2007-01-26T19:50:26Z Registry Expiry Date: 2025-01-26T19:50:26Z Registrar: Tucows Domains Inc. Registrar IANA ID: 69 Registrar Abuse Contact Email: domainabuse@tucows.com Registrar Abuse Contact Phone: +1.4165350123 Domain Status: pendingTransfer https://icann.org/epp#pendingTransfer Name Server: NS.INMOTIONHOSTING.COM Name Server: NS2.INMOTIONHOSTING.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T21:41:27Z <<<